Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis
Abstract This retrospective population-based study investigated the impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on inhaled medication adherence in people with cystic fibrosis (pwCF). Prescription refill rate (PRR) for several inhaled medications were compared before and after ETI introd...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Respiratory Research |
| Online Access: | https://doi.org/10.1186/s12931-024-03089-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594456293933056 |
|---|---|
| author | Andrea Gramegna Giuseppe Cimino Marco Cipolli Giovanna Gandini Maria Adelaide Calderazzo Angelica Profiti Federica Piedepalumbo Francesco Blasi |
| author_facet | Andrea Gramegna Giuseppe Cimino Marco Cipolli Giovanna Gandini Maria Adelaide Calderazzo Angelica Profiti Federica Piedepalumbo Francesco Blasi |
| author_sort | Andrea Gramegna |
| collection | DOAJ |
| description | Abstract This retrospective population-based study investigated the impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on inhaled medication adherence in people with cystic fibrosis (pwCF). Prescription refill rate (PRR) for several inhaled medications were compared before and after ETI introduction in three major Italian CF centers. We found a significant decrease in PRR for most inhaled antibiotics and dornase-alpha after ETI implementation.This suggests that patients may be reducing their adherence to inhaled medications, potentially due to improved respiratory symptoms and quality of life. The study highlights the challenges of maintaining adherence to chronic inhaled medications in pwCF, even after the introduction of breakthrough therapies like ETI. Monitoring adherence remains crucial for optimizing patient outcomes, and the PRR emerges as a valuable tool for tracking adherence in real-world settings. |
| format | Article |
| id | doaj-art-0879ca07aa0b4e819b36eb23ec1cbf65 |
| institution | Kabale University |
| issn | 1465-993X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Respiratory Research |
| spelling | doaj-art-0879ca07aa0b4e819b36eb23ec1cbf652025-01-19T12:36:32ZengBMCRespiratory Research1465-993X2025-01-012611310.1186/s12931-024-03089-2Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysisAndrea Gramegna0Giuseppe Cimino1Marco Cipolli2Giovanna Gandini3Maria Adelaide Calderazzo4Angelica Profiti5Federica Piedepalumbo6Francesco Blasi7Department of Pathophysiology and Transplantation, University of MilanCystic Fibrosis Regional Reference Center, A.O.U. Policlinico Umberto ICystic Fibrosis Center, AOUI VeronaPharmaceutical Service, AOUI VeronaCystic Fibrosis Center, Hospital Giovanni Paolo IITerritorial Pharmaceutical Service, ASP Vibo ValentiaDepartment of Pathophysiology and Transplantation, University of MilanDepartment of Pathophysiology and Transplantation, University of MilanAbstract This retrospective population-based study investigated the impact of elexacaftor/tezacaftor/ivacaftor (ETI) therapy on inhaled medication adherence in people with cystic fibrosis (pwCF). Prescription refill rate (PRR) for several inhaled medications were compared before and after ETI introduction in three major Italian CF centers. We found a significant decrease in PRR for most inhaled antibiotics and dornase-alpha after ETI implementation.This suggests that patients may be reducing their adherence to inhaled medications, potentially due to improved respiratory symptoms and quality of life. The study highlights the challenges of maintaining adherence to chronic inhaled medications in pwCF, even after the introduction of breakthrough therapies like ETI. Monitoring adherence remains crucial for optimizing patient outcomes, and the PRR emerges as a valuable tool for tracking adherence in real-world settings.https://doi.org/10.1186/s12931-024-03089-2 |
| spellingShingle | Andrea Gramegna Giuseppe Cimino Marco Cipolli Giovanna Gandini Maria Adelaide Calderazzo Angelica Profiti Federica Piedepalumbo Francesco Blasi Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis Respiratory Research |
| title | Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis |
| title_full | Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis |
| title_fullStr | Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis |
| title_full_unstemmed | Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis |
| title_short | Impact of elexacaftor/tezacaftor/ivacaftor (ETI) on the prescription refill rate (PRR) for inhaled medications in people with CF: an Italian multicenter analysis |
| title_sort | impact of elexacaftor tezacaftor ivacaftor eti on the prescription refill rate prr for inhaled medications in people with cf an italian multicenter analysis |
| url | https://doi.org/10.1186/s12931-024-03089-2 |
| work_keys_str_mv | AT andreagramegna impactofelexacaftortezacaftorivacaftoretiontheprescriptionrefillrateprrforinhaledmedicationsinpeoplewithcfanitalianmulticenteranalysis AT giuseppecimino impactofelexacaftortezacaftorivacaftoretiontheprescriptionrefillrateprrforinhaledmedicationsinpeoplewithcfanitalianmulticenteranalysis AT marcocipolli impactofelexacaftortezacaftorivacaftoretiontheprescriptionrefillrateprrforinhaledmedicationsinpeoplewithcfanitalianmulticenteranalysis AT giovannagandini impactofelexacaftortezacaftorivacaftoretiontheprescriptionrefillrateprrforinhaledmedicationsinpeoplewithcfanitalianmulticenteranalysis AT mariaadelaidecalderazzo impactofelexacaftortezacaftorivacaftoretiontheprescriptionrefillrateprrforinhaledmedicationsinpeoplewithcfanitalianmulticenteranalysis AT angelicaprofiti impactofelexacaftortezacaftorivacaftoretiontheprescriptionrefillrateprrforinhaledmedicationsinpeoplewithcfanitalianmulticenteranalysis AT federicapiedepalumbo impactofelexacaftortezacaftorivacaftoretiontheprescriptionrefillrateprrforinhaledmedicationsinpeoplewithcfanitalianmulticenteranalysis AT francescoblasi impactofelexacaftortezacaftorivacaftoretiontheprescriptionrefillrateprrforinhaledmedicationsinpeoplewithcfanitalianmulticenteranalysis |